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Abstract
Myofibrillar myopathies (MFM) are characterised by focal myofibrillar destruction and accumulation of myofibrillar elements as protein
aggregates. They are caused by mutations in the DES,MYOT, CRYAB, FLNC, BAG3, DNAJB6 and ZASP genes as well as other as yet unidentified
genes. Previous studies have reported changes in mitochondrial morphology and cellular positioning, as well as clonally-expanded, large-scale
mitochondrial DNA (mtDNA) deletions and focal respiratory chain deficiency in muscle of MFM patients. Here we examine skeletal muscle from
patients with desmin (n = 6), ZASP (n = 1) and myotilin (n = 2) mutations and MFM protein aggregates, to understand how mitochondrial
dysfunction may contribute to the underlying mechanisms causing disease pathology. We have used a validated quantitative immunofluorescent
assay to study respiratory chain protein levels, together with oxidative enzyme histochemistry and single cell mitochondrial DNA analysis, to
examine mitochondrial changes. Results demonstrate a small number of clonally-expanded mitochondrial DNA deletions, which we conclude are
due to both ageing and disease pathology. Further to this we report higher levels of respiratory chain complex I and IV deficiency compared to age
matched controls, although overall levels of respiratory deficient muscle fibres in patient biopsies are low. More strikingly, a significantly higher
percentage of myofibrillar myopathy patient muscle fibres have a low mitochondrial mass compared to controls. We concluded this is
mechanistically unrelated to desmin and myotilin protein aggregates; however, correlation between mitochondrial mass and muscle fibre area is
found. We suggest this may be due to reduced mitochondrial biogenesis in combination with muscle fibre hypertrophy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Myofibrillar myopathies (MFMs) are a group of myopathies
characterised by aggregation of the Z-disk proteins and focal
myofibrillar destruction. MFMs or Z-disk diseases are clinically
and genetically heterogeneous. Mutations causing MFM can be
found in genes encoding a range of Z-disk proteins including;
desmin (DES) [1], αB-crystallin (CRYAB) [2], myotilin (MYOT)
[3], filamin C (FLNC) [4], ZASP (LDB3/ZASP) [5] and Bcl2-
associated athanogene 3 (BAG3) [6]. Novel MFM causing
genes are continuously being identified and at present only 50%
of suspected MFM cases have a genetic diagnosis.
They are typically present in the third or fourth decade of life
or later, though rare cases of adolescent onset have also been
reported. Most commonly they present as distal myopathies
initially, progressing to involve proximal limb muscles.
However, myofibrillar myopathies can vary in clinical
presentation and can lead to cardiomyopathy associated with
skeletal muscle myopathy or isolated cardiomyopathy. Key
clinical patterns in presentation can be noted for some of the
causative genes; however, once more, these are not clear cut and
there are exceptions.
Mitochondrial dysfunction is a common finding in many
proteinopathies including protein aggregate myopathies
(PAMs) [7–15], and some neurodegenerative conditions [16].
Cytochrome c oxidase (COX) deficiency has been found to be
associated with clonally-expanded mtDNA rearrangements in
sarcopenia, patients with single or multiple mitochondrial DNA
(mtDNA) deletions and inclusion body myositis. However,
mtDNA point mutations [17] and depletion of mtDNA copy
number [18] may also lead to focal respiratory chain deficiency.
Previous reports have noted that both mitochondrial
morphology and positioning are altered in muscle of MFM
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patients [19], as well as the presence of clonally-expanded
large-scalemtDNAdeletions [20,21] and focal respiratory chain
deficiency [22,23].However, there have only been a fewprevious
publications to date and only small numbers of patients reported
in these studies. As such it is unclear what role, if any, clonally
expanded mtDNA deletion and mitochondrial respiratory chain
deficiency may play in the pathogenesis of myofibrillar
myopathy.
In this paper we investigate a cohort of nine genetically
determined MFM patients for evidence of mitochondrial
dysfunction. From this cohort, we further selected a group of six
patients based on the frequency of COX-deficient fibres
identified by sequential COX/SDH histochemistry to study for
presence of clonally-expanded large-scalemtDNAdeletions.We
also subjected all patientmuscle biopsies to a recently developed
immunofluorescence assay [24] to assess NDUFB8 (complex-I)
and COX-I (complex-IV) protein levels normalised to
mitochondrial mass (Porin).
2. Materials and methods
2.1. Patient cohort
Muscle biopsies were taken for diagnostic purposes from
patients with a suspected neuromuscular condition (see
Table 1). Informed consent was obtained from all patients in the
study. Ethical approval was granted by the Newcastle and North
Tyneside local research and ethics committee (LREC2002/
205). Inclusion criteria were the presence of protein aggregates
on sections stained with anti-desmin and anti-myotilin
antibodies and confirmed molecular diagnosis for MFM genes.
We studied nine MFM patients with mutations in DES (n = 6),
MYOT (n = 2) and ZASP (n = 1). A patient with compound
heterozygous RRM2B variants, leading to a disturbance of
mtDNA maintenance and multiple mtDNA deletions [25], was
used as a positive control, as well as two healthy control muscle
biopsies from individuals aged 52 and 63 years.
2.2. Histochemistry
Muscle was cryosectioned (10 μm) from transversely-
orientated muscle blocks and subjected to histochemical
reactions for the individual activities of COX, SDH and the
sequential assay of COX/SDH activity [26]. COX-deficient
fibres were counted using a stereomicroscope, by outlining the
full muscle biopsy section and using the meander scan function
in Stereo Investigator. Fibres were categorised by eye with blue
fibres being categorised as COX negative, blue-grey fibres as
intermediate negative and grey-brown fibres as intermediate
positive. Intermediate categories were included to make
comparison with immunofluorescent quantification easier. The
minimum number of fibres counted was 127, which was for
patient DES3 who had the smallest muscle biopsy section.
Serial sections were stained with Haematoxylin and Eosin
(H&E) to examine muscle morphology.
2.3. Quadruple immunofluorescence
A quadruple immunofluorescent method using antibodies
recognising laminin (membrane marker), NDUFB8 (complex I
marker), COX-I (complex IV marker), and porin as a
mitochondrial mass marker, was employed to assess the degree
of respiratory chain deficiency [24]. Briefly, one 10 μm
cryosection from each patient and age matched controls was
labelled with all four antibodies and a serial 10 μm section with
just laminin to be used as a negative (no primary antibody)
control. Sections were incubated with secondary antibodies
coupled with Alexa Fluor 405, 488, 546 and 647 (Life
Technologies). Using a Zeiss AxioImager and AxioCam MRm
with AxioVision software tiled images scanning of the full
section were acquired and stitched using ZEN (blue edition).
Analysis using IMARIS version 7.6 involved creating a surface
over the laminin staining, which was masked, allowing a second
surface covering each fibre to be created and average fluorescent
intensity for each muscle fibre to be collected.
Using values from the negative (no primary antibody)
control for each case, non-specific background was subtracted
and NDUFB8 and COX-1 intensity was normalised to porin
intensity as the mitochondrial mass marker. Control case values
then created a “normal population” for which the patient fibres
could then be assigned a z-score describing their deviation from
the normal population. Statistical analysis is described in more
detail by Rocha et al. [24]. Total fibres analysed was dependent
on section size and ranged from n = 111 to n = 1883 in patients
and controls.
Table 1
Myofibrillar myopathy patient information (n = 9). Patients are organised by gene then age order and all mutation nomenclature uses the primary transcripts for DES
(NM_001927) and MYOT (NM_006790) and for ZASP transcript variant 2 (NM_001080114.1).
Patient Gender Mutated
gene
Mutation CK Biopsy site Age at
biopsy
Age at onset
(if known)
DES 1 M DES Het. c.1069G > C, p.(Ala357Pro) 480 Quadriceps 31.2 29
DES 2 M DES Het. c.1069G > C, p.(Ala357Pro) NK NK 32.1 NK
DES 3 M DES Hom. c.46C > T, p.(Arg16Cys) 450 Quadriceps 33.8 20s
DES 4 F DES Het. c.735 + 20C > T (MAF = 0.01); c.638C > T, p.(Ala213Val) NK Quadriceps 51.3 Early childhood
DES 5 F DES Het. c.638 C > T, p.(Ala213Val) 74 Quadriceps 53 40s
DES 6 F DES Het. c.1346A > C , p.(Lys449Thr) 287 NK 64.3 46
MYOT 1 M MYOT Het. c.179C > G, p.(Ser60Cys) 446 Quadriceps 60.5 55
MYOT 2 M MYOT c.179C > G, p.(Ser60Cys) 400–500 Tibialis anterior 65.7 NK
ZASP 1 F ZASP Het. c.494C > T, p.(Ala165Val); Het. c.728C > T, p.(Pro243Leu) 300 Quadriceps 69.6 60s
DES: desmin; MYOT: myotilin; Hom.: homozygous; Het.: heterozygous; MAF: maternal allele frequency; CK: creatine kinase; NK: not known.
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2.4. Measurement of porin across the muscle fibre
A total pool of normal (n = 10), low (n = 10) and very low
porin (n = 10) fibres were selected to assess porin level across
the muscle fibre. The profile tab in ZEN (blue edition) was used
to draw a segmenting line across the full muscle fibre and
generate a graph of fluorescent intensity in each channel across
the fibre.
2.5. Mitochondrial mass
To assess mitochondrial mass, labelling of a second
marker, succinate dehydrogenase subunit A (SDHA), was
compared to porin. Cryosectioned muscle was subject to an
immunofluorescence protocol, following a similar protocol as in
Section 2.3, but without anti-COXI and replacing anti-NDUFB8
with anti-SDHA. Total fibres analysed across all patients was
n = 5565, with fibres per patient ranging from n = 114 to
n = 1283 in individual patients and controls.
2.6. Analysis of MFM protein aggregates and mitochondrial
mass
Muscle sections were co-labelled with antibodies
recognising laminin, desmin, myotilin and porin. Following
image capture, processing and analysis as in Section 2.3,
myofibres containing very low (n = 436), low (n = 338) and
normal porin (n = 150) content (across all patients) were
analysed in turn and categorised as either being positive or
negative for the presence of desmin and myotilin aggregates.
Following this, fibres with or without aggregates were plotted
against z-score for porin protein level as an indicator of
mitochondrial mass.
2.7. Laser microdissection and cell lysis
Six patients were selected for mtDNA analysis based on the
presence of COX deficient fibres. For each patient four serial
muscle sections were cryosectioned. The first and last tissue
sections underwent sequential COX/SDH histochemistry and
were used to assess deficiency of the second and third sections,
which underwent SDH histochemistry only. Sequential single
muscle fibres were laser micro-dissected from the second and
third tissue section using a PALM system (Zeiss). Fibres from
the second tissue section were captured into 15 μl SDS/EDTA/
Proteinase K single cell lysis buffer (0.5% SDS, 10 mM EDTA,
5% proteinase K) and incubated for 2 hours at 37 °C to lyse.
Fibres from the third were captured into 15 μl Tris/Tween/
Proteinase K single cell lysis buffer (0.5M Tris-HCl, 0.5%
Tween 20, 1% Proteinase K, pH 8.5) and incubated for 2 hours
at 55 °C, followed by 10 minutes at 95 °C to lyse. For each
patient 20 single fibres were analysed for both long range PCR
and real time PCR.
2.8. Long range PCR
Two rounds of PCR were employed to screen isolated muscle
fibres for large-scale mtDNA rearrangements: 1 μl cell lysate,
1× PrimeSTAR GXL reaction buffer, 0.2 μM dNTPs, 0.2 μM
forward and reverse primers and 0.625 unit polymerase, in a
total volume of 50 μl. The first round of PCR amplified a
16179 bp region using primers 2180F (nucleotides m.2180–
2209) and 1789R (nucleotides m.1760–1789) and the second
round reaction amplified a 16029 bp region using primers
2330F (nucleotides m.2330–2359) and 1789R (nucleotides
m.1760–1789) (NC_012920.1). Cycling conditions were: 35
cycles of 10 seconds at 98 °C and 11 minutes at 68 °C. PCR
products were separated through a 0.7 % agarose gel with a
1 Kb ladder used to size amplicons.
2.9. Triplex real time PCR
A triplex real time PCR assay was used to quantify mtDNA
deletion level as described previously [27]. This method
quantifies relative levels ofMT-ND4 andMT-ND1 and D-Loop,
using TaqMan chemistry. Primers and TaqMan MGB probes
used to detect MT-ND1, MT-ND4 and D-Loop have been
previously reported [27]. PCR amplification was completed in a
25 μl reaction in triplicate for each sample, with each plate
containing a serial dilution of p7D1 plasmid for standard curve
generation, as reported previously [27].
2.9.1. Analysis and statistics
Percentage classification of fibres for NDUFB8, COX-I and
porin were compared between the patient group and control
group using a Wilcoxon Signed-Rank Test. Spearman’s rank
correlation (src) was used to assess the relationship between
fibre area and complex I, complex IV and porin protein levels.
3. Results
3.1. Histology and histochemistry
H&E demonstrated a variety of pathological features
consistent with a diagnosis of myofibrillar myopathy including:
variation in fibre size, rimmed vacuoles, internal nuclei, nuclear
bags, basophilic and eosinophilic inclusions, fibre splitting,
and necrotic and regenerating fibres. Sequential COX/SDH
histochemistry showed a low number of COX-deficient fibres
(typically not more than 5%) (Table 2). Furthermore, fibres that
were pale for COX activity were also pale for SDH activity,
indicating low mitochondrial content (Fig. 1, denoted by
asterisk). Many fibres also showed a core-like depletion
of mitochondria in the centre and accumulation in the
subsarcolemmal region (Fig. 1, DES patient 2).
Table 2
COX deficiency counts for myofibrillar myopathy patients based on sequential
COX/SDH histochemistry.
Patient Total
fibres
COX-
positive
Intermediate-
positive
Intermediate-
negative
COX
negative
DES 1 494 94.3 4.45 1.01 0.202
DES 2 611 87.7 10.3 1.80 0.164
DES 3 127 81.9 18.1 0.0 0.0
DES 4 863 95.6 4.06 0.348 0.0
DES 5 1086 93.6 5.06 0.829 0.552
DES 6 248 45.16 39.1 12.9 2.82
MYOT 1 848 96.6 2.48 0.943 0.0
MYOT 2 697 91.1 5.67 3.73 0.0
ZASP 1 835 99.4 0.479 0.120 0.0
693A.E. Vincent et al. /Neuromuscular Disorders 26 (2016) 691–701
3.2. Clonally-expanded mtDNA deletions
Long rangePCRand real timePCRwereused to investigate the
presence of clonally-expanded mtDNA deletions in 20 COX-
deficient single cell lysates fromMFMpatients withDES (n = 4),
MYOT (n = 1) and ZASP (n = 1) mutations and a positive control
(patient with multiple mtDNA deletions caused by genetically
inherited pathogenic RRM2B variants). For every fibre analysed
both long range and real time PCR were performed. Long range
PCR analysis of 20 fibres from the patient with RRM2B variants
demonstrated products of varying size indicative of different sized
mtDNA deletions (Fig. 2a). In comparison to the RRM2B patient,
of the 120 fibres analysed from six MFM patients, an mtDNA
deletion was detected in only five fibres (DES4: n = 1, DES5:
n = 1 and ZASP1: n = 3). The remaining fibres either had a full-
length wild type (WT) product or failed to amplify a product
(n = 31) (Fig. 2b and c). Failure to amplify a product is common in
long range PCR from single cell lysates.This also occurred in two
fibres from the RRM2B patient. The percentage of fibres that did
not amplify is lower in theRRM2B case, likely due to the presence
of ragged-red fibres indicative of high mitochondrial mass in the
RRM2B patient and core-like fibres suggesting lowmitochondrial
mass in the MFM patients.
Real time PCR analysis showed that the majority of
individual COX-deficient myofibres obtained from the RRM2B
patient muscle contained different levels of mtDNA deletion
(Fig. 2d), which was in agreement with long range PCR results
(Fig. 2a). Real time PCR also confirmed that only a few MFM
muscle fibres contained clonally-expanded mtDNA deletion.
Of 120 fibres deletions were found by real time PCR in 12 fibres
(DES 4: n = 1, DES5: n = 2, DES7: n = 1 and ZASP1: n = 8), as
presented in Fig. 2c and d.
Out of the 120 fibres on which both long range PCR and real
time PCR were completed, a deletion was found by both
methods in five fibres and a further seven were shown to have a
deletion by real time PCR alone. In these seven fibres
unfortunately no long range product was amplified. Inclusion of
the D-loop allowed confirmation that MFM patient fibres did
not contain any deletions affecting MT-ND1 (data not shown).
This was in agreement with long range PCR.
3.3. Immunofluorescent analysis of respiratory chain
deficiency
Based on the low number of fibres in which COX-deficiency
was found by histochemistry and an mtDNA deletion detected,
we explored the nature of the respiratory chain protein
abundance in more detail. We employed a quantitative
immunofluorescence assay to assess porin, NDUFB8 (complex
I) and COX-I (complex IV) protein levels.
Immunofluorescent analysis was used to compare the
myofibrillar myopathy patients and a patient with compound
Fig. 1. Histochemistry for serial muscle sections. Sections from ZASP 1, MYOT 1 and DES 2 were subject to H&E staining, COX histochemistry, SDH
histochemistry and sequential COX/SDH histochemistry. H&E staining demonstrates morphological changes compatible with diagnosis. Many fibres appear
COX-deficient but also demonstrate low SDH reactivity, indicative of a reduction in mitochondrial mass. X, COX-deficient fibre, and asterisk (*), mitochondrial
depletion fibres. Scale bar 200 μm.
694 A.E. Vincent et al. /Neuromuscular Disorders 26 (2016) 691–701
heterozygous RRM2B variants to age matched controls.
Immunofluorescent images showed a number of fibres with
combined and isolated complex I and complex IV-deficiency, plus
fibres with reduced mitochondrial mass (Fig. 3). Respiratory
chain protein level profiles for eachMFMpatient and theRRM2B
patient can be found in Fig. 4.A summary of results can be found
in Table 3.
Controls aged 52 years and 60 years showed no complex I or
complex IV deficiency. In comparison, desmin patients showed
some levels of complex I and complex IV deficiency, reaching
6.5% and 4.2% deficient fibres for complex I and complex IV
respectively. However, respiratory chain deficiency was low in
the majority of desmin patients. Although MYOT1 also had low
levels of deficiency, MYOT2 exhibited higher levels of
deficiency with percentage deficiencies of 45.5% for complex I
and 24.7% for complex IV. Finally, the ZASP patient had 11.5%
complex I deficient fibres and 9% complex IV deficient fibres.
By comparing these patients with the RRM2B patient
(32.6% complex I and 23% complex IV deficiency), it is
apparent that MYOT2 and ZASP1 exhibit levels of deficiency
closer to that of a mitochondrial disease patient.
3.4. Reduction in mitochondrial mass
MFM patients showed very low porin fibres between
11% and 51.4%. Low and very low porin fibres are presented
by light blue and dark blue circles in the respiratory
chain profiles in Fig. 4. There was a significant difference
in percentage of normal (p = 0.03), low (p = 0.03) and very
low (p = 0.04) porin fibres between patients and controls
(tested using a Wilcoxon Signed-Rank Test.) Total fibres were
analysed and range of fibres per patient can be found in
Section 2.4.
During the image analysis process (using IMARIS), the
surfaces created above the fibres did not cover the full area
within the laminin membrane staining due to limitations in
threshold values used to generate the surfaces for analysis.
Previous reports and our findings suggest core-like depletion of
mitochondria in the intermyofibrillar regions and aggregation in
the subsarcolemmal regions. If this is the case, it is possible
that the image analysis process missed the majority of the
mitochondria located in the subsarcolemma, explaining the
high number of low porin fibres.
Fig. 2. Long range and real time PCR analysis of mtDNA deletions in each patient (n = 20). In long range PCR gels (a–c) red arrows and dashed line indicates size
of wild type mtDNA product, red asterisk (*) indicates deletion products. (a) Long range PCR results for 10 single fibre lysates relative to a wild type (WT) blood
homogenate, no template control (NTC) and 1 Kb ladder (Promega), multiple and single deletions present due to variants in RRM2B. (b) Long range PCR results
for 20 single fibre lysates from ZASP1 demonstrating 3 fibres with a single deletion. (c) Long range PCR results for 20 single fibre lysates from DES 5 demonstrating
1 fibre with an mtDNA deletion. (d) Real time PCR results for DES4, DES5, DES6, DES7, MYOT1 and ZASP1 showing ratios of ND4 to ND1. Lines represent
mean and standard error of the mean (SEM).
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In order to test whether we are underestimating the level of
porin due to our analysis methods, we analysed the fluorescent
signal intensity across a pool of normal, low and very low porin
fibres (Supplementary Fig. S1). This demonstrated a reduction
in porin fluorescent intensity across the full diameter of the
muscle fibre in both low and very low porin fibres when
compared to normal fibres.
To further verify mitochondrial mass reduction, porin was
compared to SDHA, a nuclearly encoded subunit of complex
II. Porin and SDHA immunohistochemistry was carried out
using sections from patients and controls. When SDHA is
linearly regressed against porin, the r2 values suggest a strong
positive relationship in the cases with the largest range of
porin and SDHA levels. For those cases with a smaller range
the relationship was still apparent but the r2 value was smaller
due to the spread of the data points. This indicates that
mitochondrial mass is reduced in a higher percentage of
myofibrillar myopathy patient fibres compared to controls
(2.6% and 6.4%).
3.5. Relation of respiratory chain deficiencies, mitochondrial
mass and fibre size
To determine whether levels of porin, complex I and
complex IV could be related to fibre atrophy we compared
Fig. 3. Immunofluorescent analysis of respiratory chain function. Representative immunofluorescence for NDUFB8 (complex I), porin and COX-I (complex IV) in
ZASP 1, MYOT 2 and DES 6. Complex I and complex IV deficient fibres, complex IV deficient fibres and complex I deficient fibres can be seen. Most strikingly
fibres with low porin, complex I and complex IV can be seen in a number of patients, most pronounced in ZASP1(*). Asterisk (*), low porin complex I and complex
IV; Cross, complex I and IV deficient fibres; Arrow head, complex I deficient fibres; and hash, complex IV deficient fibres. Scale bar 100 μm.
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fluorescent intensity for each channel with fibre area.
Correlation was examined using Spearman’s rank correlation
(src) coefficient (summarised in Table 4.). Plotting of muscle
fibre area against complex I level (Supplementary Fig. S2)
demonstrated a positive correlations in DES5 (src = 0.4389,
p < 0.0001), and DES3 (src = 0.4389, p = < 0.0001), a negative
correlation in DES6 (src = −0.4817, p < 0.0001). For muscle
fibre area and complex IV levels (Supplementary Fig. S3) only
very weak to no correlation was found. We also found a
negative correlation between muscle fibre area and porin level
(Supplementary Fig. S4) in ZASP1 (src = −0.4487, p < 0.0001)
and DES6 (src = −0.4583, p < 0.0001). Spearman’s rank
correlations were also significant for DES2, DES5, DES6,
MYOT1 and MYOT2; however, the correlation between porin
and muscle fibre area was weak in these patients (Table 4).
Porin level plotted against muscle fibre area, for patient ZASP1,
in particular, shows that large muscle fibres all have a low porin
level whilst smaller muscle fibres have a range of high to low
porin. Low Spearman’s rank correlations in some patients
appear to be due to the smaller range of fibre area.
3.6. Association of low porin with protein aggregates
As protein aggregates are the hallmark of myofibrillar
myopathy we hypothesised they may be mechanistically linked
to the low porin levels. Analysis of sections co-labelled with
antibodies formyotilin, desmin, porin and laminin demonstrated
a similar percentage of low and very low porin fibres relative to
controls as previously shown. Very low, low and normal
Fig. 4. Mitochondrial respiratory chain protein expression profiles. Immunofluorescence results for MFM patients and RRM2B patient positive control. Graphs
demonstrate distribution of z-scores for complex I and complex IV with each point colour coded for porin category. Number (n) of fibres analysed on each plot. (a)
DES1, (b) DES2, (c) DES3, (d) DES4, (e) DES5, (f) DES6, (g) MYOT1, (h) MYOT2, (i) ZASP1, (j) RRM2B, (k) 63 years (negative control) and (l) 52 years
(negative control). Each point gives the COX and complex-I z-scores for a single fibre and is colour coded to indicate the porin category of the fibre (very low, dark
blue; low, light blue; normal, beige; high, orange; or very high, red). Bars next to the X and Y-axes indicate category complex I or complex IV levels (dark blue,
negative; light blue, intermediate negative; light beige, intermediate positive and beige, normal). In addition solid and dashed lines running vertically and horizontally
also mark the boundaries between each category of complex I and complex IV.
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porin fibres were analysed for the presence of myotilin and
desmin aggregates. This analysis demonstrated no significant
relationship between presence of protein aggregates and porin
level (Fig. 5b). Furthermore, in fibres with aggregates in ZASP1
(the patient with the highest percentage of low porin fibres), we
found that only 22.9% had very low porin levels.
4. Discussion
Mitochondrial DNA deletions [20,21] and respiratory chain
deficiency [20,22,23] have been shown to accumulate in the
skeletal muscle of patients with myofibrillar myopathy.
Furthermore changes in mitochondrial positioning have also
been found [19]. As such, we aimed to examine a cohort
of myofibrillar myopathy patients for the presence of
mitochondrial dysfunction, and attempt to understand what
correlation, if any, this has with disease pathology.
Here we demonstrate clonally-expanded mtDNA deletions
in a small number of fibres from MFM patients by both long
range PCR and real time PCR. A further seven fibres were
found to have deletions by real time PCR but failed to amplify
a product by long range PCR, a common problem for single cell
long range PCR especially if mitochondrial content is low as in
MFM patient muscle fibres. We conclude that the low levels of
mtDNA deletions detected are likely due, at least in part, to the
age on top of the disease process. Sporadic deletions are known
to form and accumulate in mtDNA of aged muscle [28] and
here we find the highest number of deletions in the oldest
patient (ZASP1). However, due to the fact that there is only one
patient with a ZASP mutation it is difficult to conclude to what
extent this is due to age or the genotype.
In fibres where an mtDNA deletion was not detected, it is
possible that mtDNA point mutations or mtDNA depletion
may be the cause of COX deficiency. In particular, it should
be noted that based on both COX/SDH histochemistry and
immunofluorescent analysis, COX-deficient fibres are present
at lower levels comparable to those with reduced
mitochondrial mass. Both quantification of mtDNA copy
number and deep sequencing of the mitochondrial genome
would be necessary to fully assess this.
Immunofluorescent analysis demonstrated percentage
complex I and complex IV deficiency higher than would be
expected in age matched controls for four out of six desmin
patients, one of two MYOT patients and a ZASP patient.
Most strikingly porin is reduced in all patients, in a
significantly high percentage of fibres relative to controls,
indicating a reduction in mitochondrial mass. This reduction in
mitochondrial mass may simply be due to the depletion of
mitochondria in the intermyofibrillar space and aggregation in
the subsarcolemmal space previously described in myofibrillar
myopathy patients [19,22,23]. Analysis of porin fluorescent
intensity across a number of normal, low and very low porin
fibres demonstrated this is not the case and porin intensity is
reduced across the whole fibre. Furthermore, there is no
correlation between the presence of desmin and myotilin
protein aggregates and the reduction in porin. Throughout the
analysis, however, it became apparent that in some fibres where
large aggregates are present (Fig. 5c), there is a lack of porin
and therefore reduction of mitochondrial mass. In these fibres
mitochondria are accumulated in the subsarcolemmal regions
or other myofibrillar regions of the fibres, which agrees with
previous studies using electron microscopy.
It has been demonstrated that aggregate prone desmin
mutations cause a change in Ca2+ homeostatic ability, due to
lack of appropriate positioning of the mitochondria close to the
sarcoplasmic reticulum [29]. Therefore, it may be that
aggregate prone mutations in MFM related genes, including
Table 3
Immunofluorescent analysis of respiratory chain protein expression. Summary of percentage of fibres classified as complex I and complex IV negative or deficient
(negative and intermediate categories). Controls and patients are organised in age order for easy comparison.
Patient Age/
years
Complex I
negative (%)
Complex I
deficient (%)
Complex IV
negative (%)
Complex IV
deficient (%)
Total fibres
analysed
DES 1 31.2 0.00 0.00 0.00 0.00 111
DES 2 32.1 0.12 6.48 0.12 3.62 174
DES 3 33.8 0.00 0.00 0.58 4.18 162
DES 4 51.3 0.00 0.00 0.00 0.00 224
52 Years (-ve C) 52.0 0.00 0.00 0.00 0.00 581
DES 5 53.0 0.79 1.41 0.8 1.63 1883
60 Years (-ve C) 60.0 0.00 0.73 0.07 0.07 395
MYOT 1 60.5 0.18 0.18 0.12 0.44 669
DES 6 64.3 1.91 2.50 3.52 4.99 149
MYOT 2 65.7 38.5 45.51 13.57 24.73 177
ZASP 1 69.6 6.43 11.47 5.34 8.96 1348
Table 4
Summary of Spearman’s rank correlation (src) analysis of muscle fibre are area
against levels of porin, complex I and complex IV.
Patient Porin Complex I Complex IV
src p value src p value src p value
DES 1 −0.0564 0.5546 0.1389 0.144 0.09819 0.303
DES 2 −0.2492 0.0009 0.1161 0.1261 −0.1738 0.0214
DES 3 0.3776 <0.0001 0.4389 <0.0001 0.2808 0.0003
DES 4 0.06009 0.3707 0.1249 0.0619 0.05067 0.4504
DES 5 −0.1733 <0.0001 0.26 <0.0001 0.2933 <0.0001
DES 6 −0.4583 <0.0001 −0.4817 <0.0001 −0.3073 0.0001
MYOT 1 −0.2093 <0.0001 −0.09169 0.0187 −0.2006 <0.0001
MYOT 2 0.1302 0.1064 0.2428 0.0023 0.0483 0.5506
ZASP 1 −0.4487 <0.0001 −0.1716 <0.0001 −0.1634 <0.0001
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MYOT and ZASP also cause this same effect and therefore lead
to increased cytoplasmic Ca2+. An increase in cytoplasmic Ca2+
concentration in neurons has been found to increased fission
and therefore fragment the mitochondrial network [30].
Mitochondrial fusion and interaction of the mitochondrial
network are necessary for mitochondrial DNA stability and
ability to cope with mtDNA mutation [31]. So, this could
explain both the formation and accumulation of mtDNA
deletions in some MFM patients and also respiratory chain
deficiency. However, whether this could be a relevant
mechanism in the reduction of mitochondrial mass or whether
a shift in mitochondrial biogenesis and mitophagy might be
responsible is unclear.
Comparison of complex I and complex IV levels with
muscle fibre cross sectional area yielded mixed relationships,
making it hard to determine whether complex I and complex IV
levels may be linked to muscle fibre atrophy or hypertrophy. On
the other hand, comparison of muscle fibre area with porin
levels demonstrated a negative relationship in the majority of
patients. The relationship demonstrates that hypertrophic
muscle fibres with a greater area typically have a lower level of
porin than atrophic fibres with a smaller area, which have more
variable levels of porin. This might suggest that mitochondrial
mass is not involved in the process of muscle atrophy but may
indicate either a lack of mitochondrial biogenesis or increased
mitophagy during muscle fibre hypertrophy. Alternatively it
Fig. 5. Immunofluorescent analysis of mitochondrial mass and MFM aggregates. ZASP 1 as a representative example of analysis of desmin and myotilin protein
aggregation and porin levels. (a) ZASP 1 fibres classified as very low (pink), low (yellow) or normal (green) porin fibres analysed for presence of aggregates. No
clear relationship detected. Very low porin fibres accounted for 22.9% of all fibres with aggregates. (b) Immunofluorescent images from ZASP 1 showing individual
channel images (desmin, myotilin, porin) and merged. The staining demonstrates a lack of porin in regions with large aggregates (regions within dashed lines).
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could indicate that fibre atrophy is more common in oxidative
muscle fibres whilst fibre hypertrophy is more common in
glycolytic muscle fibres. It seems most likely that a lack of
mitochondrial biogenesis be responsible for the low levels of
porin in the hypertrophic muscle fibres; however, further testing
would be needed to confirm this.
The low occurrence of mtDNA deletions, lack of
relationship between complex I and IV deficiency and muscle
fibre cross sectional area and between pathological protein
aggregates and mitochondrial dysfunction, found here, are very
different to our previous findings in sporadic IBM. In sporadic
IBM, approximately 50% of COX-deficient fibres were shown
to have one or more large-scale mtDNA rearrangements [32].
Furthermore, inflammatory infiltrates correlated with the extent
of the mitochondrial respiratory chain deficiency and muscle
fibre atrophy [13]. Therefore, in comparison to IBM where we
can conclude mitochondrial dysfunction is pathologically
important, and to mitochondrial myopathies where a clear
mechanistic link exists between mutations in mtDNA
maintenance genes, mtDNA deletions and mitochondrial
respiratory chain deficiency, further work needs to be
undertaken to determine whether mitochondrial dysfunction is
pathologically relevant in MFM. Nevertheless, the decrease in
mitochondrial mass and weak relationship between
mitochondrial mass and muscle fibre cross sectional area
certainly infers that mitochondrial dysfunction may be both
mechanistically- and pathologically-relevant.
In conclusion, we have demonstrated clonally-expanded
mtDNA deletions in a small number of single cells, similar to
previous findings in muscle homogenate DNA from similar
patients [20,21], although do note the increased frequency of
these mutations in the oldest patient with a ZASP mutation.
Given this and previous work we conclude that mtDNA
deletions likely arise due to the combined effect of sarcopenia
and disease pathogenesis. We also present evidence that
myofibrillar myopathies can manifest depletion of mitochondria
and respiratory chain deficiency of varying degrees among
patients. Previous reports also report a core-like reduction of
mitochondria, something we confirm. Such a depletion of
mitochondria may be a contributing factor to overall disease
pathogenesis and could be related to muscle fibre hypertrophy.
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